



MULTIPLE SCLEROSIS SPECIALTY CARE PROGRAM

Phone: **844-378-3784** • Fax: **888-972-7058**



1 PATIENT INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Alt. Phone: _____
 Email: _____
 DOB: _____ Gender: M F Caregiver: _____
 Height: _____ Weight: _____ Allergies: _____

2 PRESCRIBER INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____
 NPI: _____ DEA: _____
 Tax I.D.: _____
 Office Contact: _____ Phone: _____

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: _____ ICD-10: _____ Relapse/Remitting Progressive
 If Relapse Remitting: Has the patient experienced a first clinical episode? Yes No Attach MRI Results Date: _____
 Past Failed Therapies: _____
 Does the patient have any contraindication(s) to therapy? No Yes If Yes: _____

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

4 INJECTION TRAINING: Pharmacist to Provide Training Patient Trained in MD Office Manufacturer Nurse Support

5 PRODUCT DELIVERY: Patient's Home Physician's Office Pharmacy to Coordinate

6 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: _____ Patient's Date of Birth: _____

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> AVONEX®	<input type="checkbox"/> 30mcg Prefilled Syringe <input type="checkbox"/> 30mcg Single Dose Vial <input type="checkbox"/> 30mcg Avonex Pen	<input type="checkbox"/> Titration: 7.5mcg weekly (over a 4 week period) until target dose is reached which is 30mcg <input type="checkbox"/> Inject 30mcg IM once a week	1 Kit	
<input type="checkbox"/> BETASERON®	<input type="checkbox"/> 0.3mg Lyophilized Powder	<input type="checkbox"/> Titration: Weeks 1-2: Inject 0.0625mg/0.25ml SC every other day Weeks 3-4: Inject 0.125mg/0.50ml SC every other day Weeks 5-6: Inject 0.1875mg/0.75ml SC every other day Weeks 7 and onward: Inject 0.25mg/1ml SC every other day <input type="checkbox"/> Inject 0.25mg (1ml) SC every other day	1 Kit	
<input type="checkbox"/> COPAXONE®	<input type="checkbox"/> 20mg Prefilled Syringe <input type="checkbox"/> 40mg Prefilled Syringe	<input type="checkbox"/> Inject 20mg SC daily <input type="checkbox"/> Inject 40mg SC three times per week <input type="checkbox"/> Other _____	1 Kit	
<input type="checkbox"/> DALFAMPRIDINE ER	<input type="checkbox"/> 10mg Tablets	<input type="checkbox"/> Recommended Dose: Take 1 tablet twice daily (approximately 12 hours apart) with or without food <input type="checkbox"/> Other _____	60	
<input type="checkbox"/> EXTAVIA®	<input type="checkbox"/> 0.3mg Lyophilized Powder	<input type="checkbox"/> Titration: Weeks 1-2: 0.0625mg/0.25ml SC every other day Weeks 3-4: 0.125mg/0.50ml SC every other day Weeks 5-6: 0.1875mg/0.75ml SC every other day Weeks 7 and onward: 0.25mg/1ml SC every other day <input type="checkbox"/> Inject 0.25mg (1ml) SC every other day	1 Kit	
<input type="checkbox"/> GILENYA®	<input type="checkbox"/> 0.25mg Capsule <input type="checkbox"/> 0.5mg Capsule	<input type="checkbox"/> (Pediatric Patients) 10 years of age and above weighing <40kg: Take one 0.25mg capsule by mouth once daily with or without food <input type="checkbox"/> (Pediatric and Adult Patients) 10 years of age and above weighing >40kg: Take one 0.5mg capsule by mouth once daily with or without food <input type="checkbox"/> Other _____		
<input type="checkbox"/> GLATOPA®	<input type="checkbox"/> 20mg Prefilled Syringe <input type="checkbox"/> 40mg Prefilled Syringe	<input type="checkbox"/> Inject 20mg SC daily <input type="checkbox"/> Inject 40mg SC three times per week and at least 48 hours apart.	30 12	
<input type="checkbox"/> PLEGRIDY®	<input type="checkbox"/> Starter Pack: 63mcg/0.5ml and 94mcg/0.5ml Prefilled Pens <input type="checkbox"/> Starter Pack: 63mcg/0.5ml and 94mcg/0.5ml Prefilled Syringes <input type="checkbox"/> 125mcg/0.5ml Prefilled Pens <input type="checkbox"/> 125mcg/0.5ml Prefilled Syringes	<input type="checkbox"/> Titration: Day 1: Inject 63mcg (0.5ml) SC Day 15: Inject 94mcg (0.5ml) SC Day 29 and every 14 days thereafter: Inject 125mcg (0.5ml) SC <input type="checkbox"/> Inject 125mcg (0.5ml) SC every 14 days	2 2	
<input type="checkbox"/> REBIF®	<input type="checkbox"/> Titration Pack <input type="checkbox"/> 22mcg Prefilled Syringe <input type="checkbox"/> 44mcg Prefilled Syringe <input type="checkbox"/> Rebidose® 22mcg Autoinjector <input type="checkbox"/> Rebidose® 44mcg Autoinjector	<input type="checkbox"/> Titration Pack Rebidose (six 8.8mcg pre-filled autoinjectors and six 22 mcgpre-filled autoinjectors) <input type="checkbox"/> For 22mcg SC 3 times per week maintenance dose: • Weeks 1 & 2: Inject 4.4mcg 3 times per week • Weeks 3 & 4: Inject 11mcg 3 times per week • Weeks 5 and onward: Inject 22mcg 3 times per week <input type="checkbox"/> For 44mcg SC 3 times per week maintenance dose: • Weeks 1 & 2: Inject 8.8mcg 3 times per week • Weeks 3 & 4: Inject 22mcg 3 times per week • Weeks 5 and onward: Inject 44mcg 3 times per week	1 Kit	
<input type="checkbox"/>				

PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: _____ Date: _____ Signature: _____ Date: _____

Substitution Permitted

Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

v9.5_112119

©2019 KloudScript, Inc. - All rights reserved.